Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Breast Neoplasms 352Neoplasm Metastasis 31Stomach Neoplasms 30HER2-positive Breast Cancer 19Neoplasms 16Breast Neoplasms, Male 16Brain Neoplasms 13Inflammatory Breast Neoplasms 12Esophageal Neoplasms 10Colorectal Neoplasms 10Triple Negative Breast Neoplasms 8Adenocarcinoma 7Prostatic Neoplasms 6Cardiotoxicity 6Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 5Lung Neoplasms 5Carcinoma, Ductal, Breast 5Biliary Tract Neoplasms 5Salivary Gland Neoplasms 4Pathologic Complete Response 4Pancreatic Neoplasms 4Meningeal Neoplasms 4Colonic Neoplasms 4Breast Diseases 4Recurrence 3Rectal Neoplasms 3Meningeal Carcinomatosis 3Gallbladder Neoplasms 3Carcinoma, Lobular 3

Interventions

pyrotinib 2pertuzumab 2Trastuzumab 2disitamab vedotin 1atezolizumab 1RC48 antibody 1Drug Therapy 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × HER2-positive Metastatic Breast Cancer × Trastuzumab × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting
312 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡